Efficacy and Safety of Hemorrane Plus Versus Hemorrane and Versus Placebo in Patients With Uncomplicated Haemorrhoids

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE3

Total Enrollment

21 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-03-30

Study Completion Date

2024-01-04

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a Multicentre, double-blind, randomised clinical trial to evaluate and compare the efficacy and safety of Hemorrane Plus (Hemorrane® + benzocaine) with Hemorrane® and with placebo in patients with uncomplicated haemorrhoids.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy and Safety Study to Treat Subjects With Symptomatic Internal Hemorrhoids

NCT01355874

Internal Hemorrhoids

TERMINATED PHASE3

Hemoclin Gel for the Treatment of Hemorrhoids

NCT05124379

Hemorrhoids Grade I and II

COMPLETED NA

Randomized Study of Oral Aesculus Hippocastanum and Combinations in Hemorrhoidal Disease After 60 Days of Treatment

NCT06705777

Haemorrhoidal Disease

COMPLETED PHASE4

Evaluation of the Effectiveness of a Topical Medical Device in Wound Healing and Symptom Relief in the Postoperative Period of Open Excisional Hemorrhoidectomy (The Emor Study)

NCT06872151

Anus Diseases Gastrointestinal Diseases Intestinal Diseases +3 more

COMPLETED PHASE4

A Study of HR18034 for Postoperative Analgesia in Subjects Undergoing Hemorrhoidectomy

NCT05769855

Postsurgical Pain Management

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Haemorrhoids Without Complication

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Hemorrane® Plus

Daily application of Hemorrane Plus (Hemorrane® + benzocaine) 10 mg/g rectal ointment + 30 mg/g benzocaine for 7 days.

Group Type EXPERIMENTAL

Hemorrane plus

Intervention Type DRUG

Hemorrane 10 mg/g rectal ointment + 30 mg/g benzocaine

Hemorrane®

Daily application of Hemorrane 10 mg/g rectal ointment for 7 days.

Group Type ACTIVE_COMPARATOR

Hemorrane

Intervention Type DRUG

Hemorrane 10 mg/g rectal ointment

Placebo

Daily application of placebo for 7 days.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Rectal ointment

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Hemorrane plus

Hemorrane 10 mg/g rectal ointment + 30 mg/g benzocaine

Intervention Type DRUG

Hemorrane

Hemorrane 10 mg/g rectal ointment

Intervention Type DRUG

Placebo

Rectal ointment

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Over 18s and both sexes.
2. Voluntary signing of informed consent.
3. Diagnosis of uncomplicated haemorrhoids: grade I or II non-thrombosed external, mixed, or internal haemorrhoids.
4. VAS of pain ≥ 5 points.
5. VAS of pruritus and stinging/burning ≥ 5 points (for each one).
6. Commitment to comply with the hygienic-dietary measures established for the general management of haemorrhoids.
7. Negative urine pregnancy test (women of childbearing age, if applicable).
8. Patients with adequate understanding of the study and ability to perform the procedures independently.

Exclusion Criteria

1. History of hypersensitivity to any of the active ingredients or components of the investigational products, as well as hypersensitivity to other local anaesthetics derived from para-aminobenzoic acid (PABA), parabens, or paraphenylenediamine (for example, hair dyes, henna tattoos).
2. Use of topical haemorrhoid medications or other topical agents for the anorectal area less than 48 hours before the start of the study (Visit 1, day 1).
3. Haemorrhoidal surgery that is scheduled between Visit 1 (day 1) and the follow-up visit Visit 3 (day 15±2).
4. Diagnosis of grade III or IV thrombosed external or internal haemorrhoids.
5. Medical history of anaemia, and/or current diagnosis of cardiac or pulmonary disease, shock, sepsis, acidosis, or genetic predisposition (NADH-cytochrome b5 reductase deficiency, glucose-6-phosphate dehydrogenase deficiency, and haemoglobin M disease); that include risk factors for methemoglobinemia.
6. Documented diagnosis of active tuberculosis.
7. Active bleeding haemorrhoids.
8. Presence of pain, stinging/burning, pruritus, anorectal bleeding or rectal bleeding for causes other than haemorrhoidal disease.
9. Presence of bacterial, viral, and/or fungal infections in the perianal area.
10. History of pancreatic pathology that may require performance of a bentiromide diagnostic test.
11. Use of any of the prohibited concomitant medications (sulfonamides, cholinesterase inhibitors, ester or prilocaine-type local anaesthetics, sodium nitrite, neurotoxic insecticides (topical malathion), aminosalicylic acid, suxamethonium, antiarrhythmics, monoamine oxidase inhibitors, tricyclic antidepressants, and PABA derivatives) less than one week prior to the start of the study (Visit 1, Day 1), or throughout the study.
12. Use of any hair dye, including those containing paraphenylene-diamine during the study, from Visit 1 (Day 1) to the follow-up Visit 3 (Day 15 ± 2).
13. Any other circumstance considered by the investigator to prevent adequate follow-up and/or adequate evolution of the response to the study treatments.
14. Pregnant women, those planning an upcoming pregnancy or breast-feeding.
15. Women of childbearing age who do not agree to take the pregnancy test and use valid contraceptive methods during the study and until the end of the use of the investigational treatment. The following are considered valid contraceptive methods: combined hormonal oral, intravaginal or transdermal contraceptives (oestrogen and progesterone), oral, injectable or implantable progesterone-based hormonal contraceptives, intrauterine device (IUD), hormone-releasing intrauterine device, bilateral tubal occlusion, vasectomised partner (as long as they are the only sexual partner of the participating patient and that the success of the intervention has been medically confirmed), or sexual abstinence (abstaining from heterosexual intercourse during the treatment period). The investigator is responsible for determining whether the patient has an appropriate contraceptive method for her participation in the study.
16. Fertile men who use condoms or have had a vasectomy (as long as the success of the intervention has been medically confirmed), or who practise abstinence (abstinence from heterosexual sexual relationships during the treatment period). The investigator is responsible for determining whether the patient has an appropriate contraceptive method for their participation in the study.
17. Patients who have had active cancer in the last five years.
18. Patients who have received an investigational drug (including vaccines) or who have used an invasive medical device in the last 30 days prior to the start of the screening phase or who are currently participating in another clinical trial.
19. Patients who have a family or professional relationship with the research team participating in the clinical study.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No